

ACC Rockies Mar. 12-15, 2017

Faculty Conflict Of Interest Disclosure



If any potentially conflicting interests exist with respect to presentation content, there is an obligation to disclose this conflict.

Please return completed form to Karen Earl:

Email: karen@ebminc.ca

Fax: (905) 607-3163

Please Check One:

I **do not** have an affiliation (financial or otherwise) with a commercial organization within the previous two (2) years that may have a direct or indirect connection to the content of this presentation.

I **have/had** an affiliation (financial or otherwise) with a commercial organization within the previous two (2) years that may have a direct or indirect connection to the content of this presentation.

If this option applies, please provide details by completing the rest of this form.

Relevant Disclosure Relationships

1. Consulting Fees/Honoraria:

Including honoraria from a third party, gifts or other consideration, or "in kind" compensation, whether for consulting, lecturing, travel, service on an advisory board, legal testimony or consultation for any other similar purpose in the prior two calendar years.

- | | |
|--|--|
| <input type="checkbox"/> None | <input type="checkbox"/> Johnson & Johnson |
| <input type="checkbox"/> Abbott Vascular | <input type="checkbox"/> Medtronic |
| <input checked="" type="checkbox"/> AstraZeneca | <input type="checkbox"/> Merck |
| <input checked="" type="checkbox"/> Bayer | <input type="checkbox"/> Novartis |
| <input type="checkbox"/> Boehringer Ingelheim | <input checked="" type="checkbox"/> Pfizer |
| <input type="checkbox"/> Boston Scientific | <input type="checkbox"/> Roche |
| <input type="checkbox"/> Bristol-Myers Squibb | <input type="checkbox"/> sanofi |
| <input type="checkbox"/> Edwards Lifesciences | <input type="checkbox"/> Schering Plough |
| <input type="checkbox"/> Eli Lilly | <input type="checkbox"/> Servier |
| <input type="checkbox"/> GlaxoSmithKline | <input type="checkbox"/> St. Jude Medical |
| <input checked="" type="checkbox"/> Other, please specify: Amgen | |

2. Officer, Director, Or In Any Other Fiduciary Role:

Whether or not remuneration is received for service.

- None
- Yes, please specify the company/organization: Canadian Centre for Clinicians and Scientists

ACC Rockies Mar. 12-15, 2017

Faculty Conflict Of Interest Disclosure



3. Clinical Trials:

Participating in a clinical trial sponsored by a commercial organization that may have a direct or indirect connection to the content of my presentation.

<input type="checkbox"/>	None	<input checked="" type="checkbox"/>	Johnson & Johnson
<input checked="" type="checkbox"/>	Abbott Vascular	<input type="checkbox"/>	Medtronic
<input checked="" type="checkbox"/>	AstraZeneca	<input type="checkbox"/>	Merck
<input checked="" type="checkbox"/>	Bayer	<input type="checkbox"/>	Novartis
<input checked="" type="checkbox"/>	Boehringer Ingelheim	<input checked="" type="checkbox"/>	Pfizer
<input type="checkbox"/>	Boston Scientific	<input type="checkbox"/>	Roche
<input checked="" type="checkbox"/>	Bristol-Myers Squibb	<input type="checkbox"/>	sanofi
<input checked="" type="checkbox"/>	Edwards Lifesciences	<input type="checkbox"/>	Schering Plough
<input type="checkbox"/>	Eli Lilly	<input type="checkbox"/>	Servier
<input type="checkbox"/>	GlaxoSmithKline	<input type="checkbox"/>	St. Jude Medical
Other, please specify:			

4. Ownership/Partnership/Principal:

Excluding mutual diversified funds.

None
 Yes, please specify the company/organization:

5. Intellectual Property Rights:

Includes patent or other intellectual property in a for-profit corporation.

None
 Yes, please specify the company/organization:

6. Other Financial Benefit:

Includes patent or other intellectual property in a for-profit corporation.

None
 Yes, please specify the company/organization:

7. Will you describe the off-label use of a device, product, or drug that is approved for another purpose?

None
 Yes (If Yes, you must disclose this to the audience within your presentation)

I confirm that as a faculty speaker at ACC Rockies 2017, I will indicate to the audience the existence of any potential bias, direct or indirect, that might be perceived to influence my presentation(s).

Printed Name Robert Welsh

Signature 

Date Feb 22, 2017

Please return completed form to Karen Earl: email karen@ebminc.ca or fax (905) 607-3163.